KPRX: Kiora Pharma Price-to-Revenue Coefficient

Symbol and logo of brand kiorapharma.com (KPRX)

Kiora Pharmaceuticals (KPRX) is facing a liquidity shortage due to medical testing costs. However, the creation of a unique patent environment around KIO-301 molecules ties clinics to the company's protocols. The specifics of the sector eliminate economic dependency, as retinal treatment is critical. Examining the P/S multiple trend on GURU.Markets, it is evident that 357.40 represents the current level of the metric.

KPRX Kiora Pharmaceuticals Inc. Price-to-Revenue Ratio (05/12/2024 - 08/09/2025)

Kiora Pharmaceuticals (KPRX) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Stock Price kiorapharma.com|KPRX - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Kiora Pharma|KPRX - Total Company Value
- company book value details:
Net Asset Value per Share Kiora Pharmaceuticals|KPRX - Company Book Value|Market Value to Book Value kiorapharma.com|KPRX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Kiora Pharmaceuticals|KPRX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital kiorapharma.com|KPRX - Company Debts|Debts to Book Capitalization Ratio Kiora Pharma|KPRX - Company Long-Term Debts|Company Short-Term Loans and Borrowings Kiora Pharmaceuticals|Quick Ratio kiorapharma.com
- earnings and multiples data:
KPRX - Company Net Income|Expected Net Income Kiora Pharmaceuticals|KPRX - Price to Earnings Ratio|Projected Price to Earnings kiorapharma.com|KPRX - PEG Multiple|EV/EBITDA Multiple Kiora Pharma|KPRX - Operating profit EBITDA|Net earnings per share for the last 12 months Kiora Pharmaceuticals|KPRX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months kiorapharma.com|KPRX - Net earnings per share growth this year|Earnings growth forecast for next year Kiora Pharmaceuticals
- total revenue and sales volume data:
KPRX - Company Sales|Company Projected Revenue Volume kiorapharma.com|KPRX - P/S Multiple|Market Cap to Expected Sales Ratio Kiora Pharma
Fundamental company analysis:Kiora Pharmaceuticals Inc. - KPRX
Signature product of Kiora Pharmaceuticals, Inc.

The ratio of Kiora Pharmaceuticals (KPRX) market capitalization to its annual revenue determines the value of each dollar of sales, allowing investors to assess the asset's fundamental overvaluation amid tight monetary policy. By analyzing the company's rolling P/S, market expectations can be correlated with the efficiency of ESG standard implementation in the synthesis of ophthalmological molecules, confirming management transparency and long-term business sustainability.

Competing companies

P/S Multiple alcon.com (ALC)|P/S Multiple BLCO (Bausch + Lomb)|Price-to-Revenue Coefficient Glaukos Corp (GKOS)|APLS - Price-to-Revenue Ratio|Price to Sales Belite Bio, Inc|Ocular Therapeutix (OCUL) - Price-to-Revenue Ratio|harrowinc.com - Market Capitalization-to-Revenue Ratio|VRDN (Viridian Therapeutics, Inc.) - P/S Multiple|P/S Multiple LENZ Therapeutics Inc|Market Cap to Revenue OCS (Oculis AG)|EYPT (EyePoint Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kodiak Sciences Inc. KOD|ALDX (Aldeyra Therapeutics Inc.) - Price-to-Sales Ratio|Kala Pharmaceuticals - P/S Multiple|Market Capitalization-to-Revenue Ratio IRD (Opus Genetics Inc)|OKYO: P/S Multiple|Adverum Biotechnologies, Inc. (ADVM) - P/S Multiple|Price-to-Revenue Ratio Outlook Therapeutics|CLSD: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NovaBay Pharmaceuticals (NBY)|Market Cap to Revenue alimerasciences.com ALIM|P/S Multiple EYEN (Eyenovia)|P/S Multiple Guardion Health GHSI|Ocuphire Pharma, Inc. - P/S Multiple|opthea.com (OPT) - Market Cap to Revenue